Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506329 | 1.00 | HSD11B1 (0.91) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6026817 | 0.88 | KDM4E (1.00) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29967633 | 0.88 | KDM4E (1.00) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10031608 | 0.87 | ALDH1A1 (0.74) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25735979 | 0.87 | HSD11B1 (0.91) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6027289 | 0.87 | ALDH1A1 (0.74) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6027723 | 0.84 | ALDH1A1 (0.70) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14988922 | 0.84 | ALDH1A1 (0.74) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3006653 | 0.84 | HSD11B1 (0.67) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3925050 | 0.84 | HSD11B1 (0.67) | HSD11B1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | HSD11B1 693/4885KDM4E 898/4885ALDH1A1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.